Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Durvalumab Wins FDA Approval in Limited-Stage SCLC

2.

Taking the "Boob Bus"; Reluctance to Grant Prior Authorization; Alcohol's Carcinogenic Potential?

3.

Clinical trial sees dramatic results using radiation to treat breast cancer

4.

Can taking vitamin D supplements every day lower the mortality rate from cancer?

5.

First-Line Combination for Bladder Cancer Not Eligible for Cisplatin Just Misses Positive Outcome.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot